Raven Biosciences

Raven Biosciences is a computational life sciences company specializing in the design and optimization of molecules across all major modalities using cutting-edge in-silico technologies. By combining deep expertise in artificial intelligence, machine learning, and medicinal chemistry, Raven Biosciences supports drug discovery and development teams working with small molecules, macrocycles, peptides, antibodies, enzymes, proteins, and nucleotides.

The company serves a broad range of life sciences clients — from pharmaceutical and biotech companies to investment-backed drug development programs — providing both software platforms and collaborative scientific services that maximize value at every stage of the molecular design process.

Molecule Modalities and Application Areas

• Small molecules: Drug discovery and development support through in-silico design and optimization workflows.
• Macrocycles and peptides: Optimization and design of complex cyclic and linear peptide structures.
• DNA/RNA: Design and evaluation of primers and diagnostic nucleotide sequences.
• Antibodies: Characterization and optimization of antibody candidates, including epitope identification and next-generation antibody development.
• Enzymes: Optimization and repurposing of enzymes for novel applications.
• Other modalities: Druggability assessment and target deconvolution services for emerging therapeutic targets.

Key Products and Platforms

• ChemX: A machine learning platform purpose-built for molecules, enabling users to wrangle chemical data, train and compare predictive models, and perform virtual screening. ChemX includes explainability analyses to help scientists understand structure-activity relationships, making it accessible for medicinal chemists and computational teams alike.
• JADBio: A machine learning platform designed for the broader life sciences domain, supporting data-driven discovery and analysis across biological datasets.
• EpiC: An epitope characterization platform for antibodies. EpiC has been used to accurately identify and characterize the epitopes of clinical-stage antibodies, providing critical insights that enable the discovery of novel antibodies with similar binding characteristics and supporting next-generation therapeutic development.
• Enzyme Discovery Platform: A forthcoming platform focused on enzyme discovery, currently in development and coming soon.

Client Partnerships and Notable Use Cases

• Raven Biosciences has partnered with multiple portfolio companies through Marigold Investment Management, delivering value through their combined expertise in AI, in-silico methods, and medicinal chemistry.
• The company has supported drug development programs for Refoxy Pharmaceuticals across multiple engagements, contributing to drug design and discovery initiatives.
• Alligator Bioscience used the EpiC platform to characterize the epitope of their phase 3-ready antibody, mitazalimab, gaining novel insights into CD40 antibody binding characteristics that enabled development of next-generation conditional CD40 agonists.
• Senior medicinal chemists have highlighted ChemX for its ease of use in data wrangling, model training, virtual screening, and interpretability of machine learning outputs.

Raven Biosciences combines proprietary software platforms with deep scientific collaboration to accelerate molecular design and drug development across the life sciences industry.